Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The influenza virus continues to impose a significant yearly burden on society due to the variable efficacy of seasonal vaccines. Further strains like H5N1, that are not included in the seasonal influenza vaccine, may spill over from animal reservoirs and more significantly impact human health. A broadly acting subunit vaccine can offer protection across multiple strains but would have low immunogenicity without an adjuvant, which are currently limited and require delivery systems to mitigate side effects. Further, antigen delivery can be enhanced with carrier systems to provide dose sparing, and thermostability. This study explores acetalated dextran microparticles (Ace-DEX MPs) encapsulating cGAMP and computational optimized broadly reactive antigen (COBRA) hemagglutinin (HA) proteins, to form a multivalent influenza vaccine. Previous research has shown that Ace-DEX cGAMP MPs with varying degradation kinetics can modulate the immune response. Here, we investigate the effects of mixing MPs with different degradation rates to optimize the immune response. Mice vaccinated with slower-degrading cGAMP MPs exhibited higher IgG2a titers and IL-2 producing splenocytes, while those vaccinated with a mix of fast and slow-degrading cGAMP MPs had the highest IFN-γ producing splenocytes. The protection afforded in mice was also shown in ferrets with a H1, H3 and H5 trivalent COBRA formulation adjuvanted by slow degrading cGAMP MPs. Furthermore, using Ace-DEX MPs encapsulating two broadly reactive COBRA H1 and H3 immunogens in particles with fast and slow degradation rates, co-delivered with cGAMP MPs, resulted in less single antigen dominance when the more dominant antigen was encapsulated in the slowest degrading MP. This work underscores the utility of Ace-DEX MPs as a vaccine delivery platform and the impact of MP degradation kinetics on vaccine efficacy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12255521PMC
http://dx.doi.org/10.1016/j.jconrel.2025.113936DOI Listing

Publication Analysis

Top Keywords

cgamp mps
20
influenza vaccine
12
degradation rates
12
ace-dex mps
12
mps
9
mps encapsulating
8
broadly reactive
8
degradation kinetics
8
immune response
8
producing splenocytes
8

Similar Publications

The influenza virus continues to impose a significant yearly burden on society due to the variable efficacy of seasonal vaccines. Further strains like H5N1, that are not included in the seasonal influenza vaccine, may spill over from animal reservoirs and more significantly impact human health. A broadly acting subunit vaccine can offer protection across multiple strains but would have low immunogenicity without an adjuvant, which are currently limited and require delivery systems to mitigate side effects.

View Article and Find Full Text PDF
Article Synopsis
  • Seasonal influenza viruses lead to epidemics in humans, while avian influenza poses a serious risk due to its ability to infect multiple species and cause severe illness, highlighting the need for a universal vaccine.
  • The study explores using cGAMP, an adjuvant that boosts immune response through the STING pathway, encapsulated in Ace-DEX microparticles to enhance vaccine efficacy; specifically, it evaluates COBRA vaccine candidates in mice.
  • The results showed that cGAMP-adjuvanted COBRA vaccines provoked strong immune responses, including higher specific antibodies and reduced viral impact, proving their potential as a universal influenza vaccine for both seasonal and pre-pandemic strains.
View Article and Find Full Text PDF

Influenza viruses cause a common respiratory disease known as influenza. In humans, seasonal influenza viruses can lead to epidemics, with avian influenza viruses of particular concern because they can infect multiple species and lead to unpredictable and severe disease. Therefore, there is an urgent need for a universal influenza vaccine that provides protection against seasonal and pre-pandemic influenza virus strains.

View Article and Find Full Text PDF
Article Synopsis
  • The traditional flu vaccines are made from inactivated viruses produced in chicken eggs, but this process is slow and can lead to mismatched strains, affecting vaccine efficacy.
  • Subunit-based vaccines offer quicker production but often need adjuvants like MF59, which primarily generates a helper T-cell type 2 (Th2) immune response, less optimal for strong protection against influenza.
  • A study used acetalated dextran (Ace-DEX) to create microparticles that effectively encapsulate the Th1-stimulating adjuvant cGAMP, demonstrating that these particles provide stronger immune responses compared to conventional adjuvants in mice.
View Article and Find Full Text PDF

Humoral Response to the Acetalated Dextran M2e Vaccine is Enhanced by Antigen Surface Conjugation.

Bioconjug Chem

August 2023

Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.

Article Synopsis
  • * A universal vaccine approach targeting a specific, conserved protein (M2e) in the influenza virus could improve immunity; however, M2e is not very effective on its own.
  • * New research shows that attaching M2e to a delivery system (microparticles with cGAMP) enhances its effectiveness, allowing for better T-cell and B-cell responses, and resulting in stronger protection in vaccinated mice against severe influenza challenges.
View Article and Find Full Text PDF